Moomoo AI 已提取核心信息
Ardelyx, Inc., a biopharmaceutical company, has filed a new Form S-8 registration statement with the Securities and Exchange Commission (SEC) on February 27, 2024. This filing pertains to the registration of additional shares for the company's equity incentive plans. Specifically, Ardelyx is registering an additional 9,298,127 shares of common stock under its 2014 Equity Incentive Award Plan and 5,750,000 shares under its 2016 Employment Commencement Incentive Plan. These shares are now available for grant following the automatic annual increase provisions and the action of the Board of Directors on January 16, 2024. The registration statement incorporates by reference several previous filings, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The new shares are intended for issuance as awards under the plans are exercised and/or vest, with the aim to incentivize and retain employees.
Ardelyx, Inc., a biopharmaceutical company, has filed a new Form S-8 registration statement with the Securities and Exchange Commission (SEC) on February 27, 2024. This filing pertains to the registration of additional shares for the company's equity incentive plans. Specifically, Ardelyx is registering an additional 9,298,127 shares of common stock under its 2014 Equity Incentive Award Plan and 5,750,000 shares under its 2016 Employment Commencement Incentive Plan. These shares are now available for grant following the automatic annual increase provisions and the action of the Board of Directors on January 16, 2024. The registration statement incorporates by reference several previous filings, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The new shares are intended for issuance as awards under the plans are exercised and/or vest, with the aim to incentivize and retain employees.
生物制药公司Ardelyx, Inc. 已于2024年2月27日向美国证券交易委员会（SEC）提交了新的S-8表格注册声明。该文件涉及为公司股权激励计划注册额外股份。具体而言，Ardelyx将根据其2014年股权激励奖励计划再注册9,298,127股普通股，根据其2016年就业开始激励计划注册5,75万股普通股。根据年度自动增长规定以及董事会于 2024 年 1 月 16 日采取行动，这些股票现在可供授予。注册声明以引用方式纳入了先前的几份文件，包括公司截至2023年12月31日财年的10-K表年度报告。新股计划在行使和/或归属计划下的奖励时发行，目的是激励和留住员工。
生物制药公司Ardelyx, Inc. 已于2024年2月27日向美国证券交易委员会（SEC）提交了新的S-8表格注册声明。该文件涉及为公司股权激励计划注册额外股份。具体而言，Ardelyx将根据其2014年股权激励奖励计划再注册9,298,127股普通股，根据其2016年就业开始激励计划注册5,75万股普通股。根据年度自动增长规定以及董事会于 2024 年 1 月 16 日采取行动，这些股票现在可供授予。注册声明以引用方式纳入了先前的几份文件，包括公司截至2023年12月31日财年的10-K表年度报告。新股计划在行使和/或归属计划下的奖励时发行，目的是激励和留住员工。
有用
没用